SANCILIO Frederick (US),САНЧИЛИО Фредерик (US),PERSICANER Peter (US),ПЕРСИКАНЕР Питер (US),CACACE Janice (US),КАКАЧЕ Дженис (US),DAHIM Mohand (US),ДАХИМ Моханд (US),SANCILIO Frederick,САНЧИЛИО Фредерик,PERSICANER Peter,ПЕРСИКАНЕР Питер,CACACE Janice,КАКАЧЕ Дженис,DAHIM Mohand,ДАХИМ Моханд
申请号：
RU2014141406
公开号：
RU0002633862C2
申请日:
2013.03.11
申请国别(地区):
RU
年份:
2017
代理人:
摘要：
FIELD: pharmacology.SUBSTANCE: invention is a method of treating a cardiovascular disease or condition in a patient comprising administering to said patient, orally or parenterally, a pharmaceutical composition that independently forms micelles upon contact with an aqueous medium to form spherical micelles that have an average diameter of 1 mcm to 10 mcm And ensure the absorption of omega-3 fatty acid esters practically independently of any food influence, or stable micelles pre-formed from mentioned composition in an amount therapeutically effective to reduce one or more of the symptoms of said cardiovascular disease or condition. Mentioned pharmaceutical composition comprises: (a) from 60% (w/w) to 85% (w/w) of at least one omega-3 fatty acid ester selected from the group consisting of an all-Z omega-3)-5,8,11,14,17-eicosapentaenoic acids (EPA), ester (all-Z omega-3)-4,7,10,13,16,19-docosahexaenoic acids (DHA), hexadecatrienic acid ("NTA" or 16:3 (n-3) or all-Z-7,10,13-hexadecatrienoic acid), α-linolenic acid ("ALA" or 18:3 (n-3) or all-Z-9,12,15-octadecatrienoic acid), stearidonic acid ("SDA" or 18:4 (n-3) or all-Z-6,9,12,15-octadecatetraenoic acid Slots), eicosatrienoic acid ("ETA" or 20:3 (n-3) or all-Z-11,14,17-eicosatrienoic acid), eicosatetraenoic acid ("ETA" or 20:4 (n-3)), ("HPA" or 21:5 (n-3) or all-Z-6,9,12,15,18-geyeykozapentaenoic acid), docosapentaenoic acid ("DPA", or clupanodonic acid, or 22:5 (n-3), or all-Z-7,10,13,16,19-docazapentenoic acid)； Tetrakosapentaenoic acid (24:5 (n-3) or all-Z-9,12,15,18,21-tetrakosapentaenoic acid) and tetracosahexaenoic acid (nisic acid or 24:6 (n-3) or all-Z-6 , 9,12,15,18,21-tetracosahexaenoic acid)； And (b) a surfactant which contains, in combination, at least one non-ionic polyoxyethylene glycol and sorbitan alkyl ester (polysorbate) selected from the group consisting of polyoxyethylene (20) sorbitan monolaurate (polysorbate 20), polyoxyethylene (20) sorbitan monopalmitate (Polysorbate 40), polyoxyethylene (20) s
